Significados de rosiglitazone en inglés

In both adult and aged animals, bone volume was significantly decreased by rosiglitazone.

Responses to rosiglitazone were compared with placebo using paired t-tests.

There were no major adverse effects attributable to rosiglitazone.

DiBP and rosiglitazone additionally reduced fetal plasma insulin levels.

Glimepiride and rosiglitazone significantly increased body weight and metformin reduced body weight during the study period.

However, the role of rosiglitazone in regulating LPS-induced vascular inflammation has yet to be fully elucidated.

Therefore, rosiglitazone might alter the biological effects of fatty acids in these cells and in atherosclerosis.

Between-group comparisons also showed a significant relative improvement in FMD in exercise patients compared with rosiglitazone.

Glaxo now is facing lawsuits from patients claiming harm from the drug, known generically as rosiglitazone.

Top FDA officials have disagreed and Glaxo has vigorously defended the drug, known generically as rosiglitazone.

Conversely, recently published meta-analyses suggested an increased cardiovascular risk and myocardial infarction rate associated with rosiglitazone therapy.

As for side effects, rosiglitazone and pioglitazone may cause increased plasma volume, edema and dose-related weight gain.

Therefore, the effects of rosiglitazone on the coronary circulation and any potential vascular targets need to be elucidated.

Daily morning oral doses of 8 mg rosiglitazone were administered for 15 days.

The level of IL-10 in portal vein was markedly up-regulated in rosiglitazone group as compared with vehicle group.

Metabolic and high content imaging data of spheroids exposed to an adipose-targeting drug, rosiglitazone, resulted in dose-responsive behavior.